The strong clinical data for casdatifan could drive investor interest despite declining revenue, but traders should monitor upcoming data readouts in 2026 and the futility analysis of the STAR-121 program which could impact R&D expense trajectory.
RCUS drugs
RCUS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 26 $19.54entry
- T+1 · 9mo ago +4.25%α +4.73% · $20.37
- T+5 · 9mo ago +13.66%α +14.82% · $22.21
- T+20 · 8mo ago +8.55%α +14.96% · $21.21
- T+60 · 6mo ago +19.91%α +11.73% · $23.43
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arcus Biosciences reported Q4 and full-year 2025 financial results, highlighting strong clinical data for its drug candidate casdatifan in kidney cancer, including a median progression-free survival of 15.1 months and a 45% response rate. The company maintains a robust $1 billion cash position with runway into 2028, while R&D expenses increased to $121 million in Q4. Revenue declined slightly to $33 million from $36 million year-over-year.
Key Financial Metrics
Key Facts
- Updated data for casdatifan showed 15.1 months median PFS and 45.2% confirmed response rate in 100mg cohort
- Cash, cash equivalents and marketable securities were $1.0 billion as of December 31, 2025
- Q4 2025 revenue was $33 million, down from $36 million in Q4 2024
- Q4 2025 R&D expenses were $121 million, up from $111 million in Q4 2024
- Net loss was $106 million for Q4 2025, compared to $94 million for Q4 2024
- Company expects cash runway until at least second half of 2028
Financial Impact
Revenue decreased by $3 million year-over-year while R&D expenses increased by $10 million, resulting in a wider net loss of $106 million (up from $94 million)
Risk Factors
- R&D expenses increased while revenue declined, widening net loss
- Futility analysis of STAR-121 program could lead to termination of key development program
- Dependence on successful clinical trial outcomes for casdatifan and quemliclustat
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001724521-26-000007 |
| Document: 0001724521-26-000007-index-headers.html | 0001724521-26-000007 |
| Document: 0001724521-26-000007-index.html | 0001724521-26-000007 |
| Document: 0001724521-26-000007.txt | 0001724521-26-000007 |
Track record
13 reports on RCUS
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +4.24% at T+1 after the Oct 21, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 16, 2026today Institutional Cluster Neutral 3/10 Entry $16.95 Now $16.86 −0.53% settles Nov 23
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $18.95 to $16.86 Now $16.86 −11.03% ▼ −11.03% −9.34% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $17.69 to $17.77 Now $16.86 −4.69% ▲ +0.45% −2.84% vs SPY
- Oct 23, 202624d ago 8-K Bearish 5/10 Entry $17.76 to $18.19 Now $16.86 +5.07% ▼ −2.42% −3.68% vs SPY
- Oct 22, 202625d ago 424B5 Bearish 6/10 Entry $18.54 to $18.19 Now $16.86 +9.06% ▲ +1.89% +1.33% vs SPY
- Oct 21, 202626d ago 424B5 Bearish 5/10 Entry $19.36 to $18.61 Now $16.86 +12.91% ▲ +3.87% +4.58% vs SPY
- Oct 21, 202626d ago 8-K Neutral 4/10 Entry $19.36 to $18.61 Now $16.86 −12.91% ▼ −3.87% −4.58% vs SPY
- Oct 20, 202627d ago 8-K Neutral 4/10 Entry $23.75 to $18.14 Now $16.86 −29.01% ▼ −23.62% −23.70% vs SPY
- Jul 9, 202618w ago 144 Neutral 3/10 Entry $28.92 to $26.64 Now $16.86 −41.70% ▼ −7.88% −7.32% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 2/10 Entry $26.62 to $24.55 Now $16.86 −36.66% ▼ −7.79% −7.85% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers